Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Note 11 - Research and Development

v3.8.0.1
Note 11 - Research and Development
12 Months Ended
Dec. 31, 2017
Statement Line Items [Line Items]  
Disclosure of research and development expense [text block]
11.
Research and Development:
 
Components of research and development expenses are as follows:
 
    Year ended
December 31,
2017
    Year ended
December 31,
2016
    Year ended
December 31,
2015
 
          As recast
(note 3(b))
    As recast
(note 3(b))
 
                   
Research and Development excluding salaries   $
4,573
    $
4,860
    $
3,131
 
CrystalGenomics Option Fee (a)    
-
     
1,000
     
-
 
Salaries    
1,451
     
1,691
     
1,528
 
Stock-based compensation    
214
     
247
     
183
 
Depreciation of equipment    
36
     
36
     
23
 
    $
6,274
    $
7,834
    $
4,865
 
 
During the year ended
December 
31,
2016,
the Company paid
$1.0
million to CrystalGenomics for an option fee related to the
CG’806
technology.